Aclarion Launches The Clinical Utility And Economic Trial To Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans
Portfolio Pulse from Benzinga Newsdesk
Aclarion, Inc. has launched the CLUE Trial to assess how often Nociscan's AI-generated biomarker data influences changes in surgical treatment plans for chronic low back pain. This trial will involve multiple physicians and sites, contributing to Aclarion's clinical evidence.
August 21, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclarion's launch of the CLUE Trial could enhance the perceived value of its Nociscan tool, potentially impacting its stock positively if results show significant changes in surgical plans.
The CLUE Trial aims to demonstrate the practical impact of Nociscan's AI data on surgical decisions. Positive results could increase demand for Aclarion's technology, potentially driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100